U065 - Update on Cutaneous Reactions to Targeted and Immune Cancer Therapy
Sunday, March 3; 4:30 PM - 5:30 PM
Following this course, the attendee should be able to:
- Diagnose and manage cutaneous adverse events to novel cancer therapies
- Correlate cutaneous adverse events to prognostic or toxicity indicators
- Formulate a team-based treatment plan for cutaneous adverse events in cancer patients
Immune checkpoint inhibitors (anti CTLA4, anti PD1) and targeted small molecule inhibitors (BRAFi, EGFRi, etc) are being utilized widely in cancer therapy. This session is an update on cutaneous adverse events, focusing on newly described reactions and management strategies. Additionally, correlations between cutaneous and non-cutaneous toxicities as well as using adverse events as prognostic indicators will be reviewed.
This activity has been approved by the American Board of Dermatology (ABD) for up to 10 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org.
- Patel, Anisha, MD: Novartis Pharmaceuticals Corp. – A(Fees);
Dr. Patel / Update on Cutaneous Reactions to Targeted and Immune Cancer Therapy